Hajiaghamohammadi AA et al. Treatment of Non Alcoholic Fatty Liver Disease syndrome not optimally responsive to metformin. Hum Reprod. 2003;18(8):1618-25. 5. Haas DA, Carr BR, Attia GR. Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome. Fertil Steril. 2003;79(3):469-81. 6. Harborne L, Fleming R, Lyall H, Norman J, Sattar N. Descriptive re- view of the evidence for the use of metformin in polycystic ovary syndrome. Lancet. 2003;361(9372):1894-901. 7. Katsiki N, Hatzitolios AI. Insulin-sensitizing agents in the treat- ment of polycystic ovary syndrome: an update. Curr Opin Obstet Gynecol. 2010;22(6):466-76. 8. Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (met- formin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inosi- tol) for polycystic ovary syndrome. Cochrane Database Syst Rev. 2003(3):CD003053. 9. Cho LW, Kilpatrick ES, Keevil BG, Coady AM, Atkin SL. Effect of metformin, orlistat and pioglitazone treatment on mean insu- lin resistance and its biological variability in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2009;70(2):233-7. 10. Ortega-Gonzalez C, Luna S, Hernandez L, Crespo G, Aguayo P, Arteaga-Troncoso G, et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(3):1360-5. 11. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovas- cular risk in non-alcoholic fatty liver disease (NAFLD): a system- atic review and meta-analysis of randomised trials. Diabetologia. 2012;55(4):885-904. 12. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastro- enterology. 2008;135(4):1176-84. 13. Hashemi SJ, Hajiani E, Haidari Sardabi E. A placebo-controlled tri- al of silymarin in patients with nonalcoholic fatty liver disease. Hepat Mon. 2009;9(4):265-70. 14. Velussi M, Cernigoi AM, De Monte A, Dapas F, Caffau C, Zilli M. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol. 1997;26(4):871-9. 15. Federico A, Trappoliere M, Tuccillo C, de Sio I, Di Leva A, Del Vec- chio Blanco C, et al. A new silybin-vitamin E-phospholipid com- plex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations. Gut. 2006;55(6):901-2. 16. Hajaghamohammadi AA, Ziaee A, Rafiei R. The efficacy of silyma- rin in decreasing transaminase activities in non-alcoholic fatty liver disease: A randomized controlled clinical tria. Hepat Mon. 2008;8(3):191-5. 6 Hepat Mon. 2012;12(8):e6099